Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lymphoma, Follicular 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor and Lymphoma Malignancies 1Advanced Solid Neoplasms 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lymphoma × TAK-659 × Clear all
NCT03238651 2023-02-08

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Calithera Biosciences, Inc

Phase 1 Terminated
17 enrolled 24 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT03359733 2023-02-08

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Calithera Biosciences, Inc

Phase 1 Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡